Study Suggests Ebola Antibody Ineffective Against Bundibugyo Virus Outbreak

A recent study in Nature Communications indicates that the approved Ebola monoclonal antibody, mAb114 (Ebanga), may not be effective against the ongoing 2026 Bundibugyo virus disease (BVD) outbreak. Structural models suggest the antibody targets a different viral epitope due to key mutations in the Bundibugyo virus glycoprotein. This highlights the critical need to test treatments against specific viral species to ensure efficacy during outbreaks.